Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652934 | 1.00 | MRGPRX1 (0.30) | MRGPRX1 | |
| SCHEMBL4652906 | 0.82 | — | — | |
| SCHEMBL4652901 | 0.82 | — | — | |
| SCHEMBL4652898 | 0.82 | — | — | |
| SCHEMBL5476754 | 0.73 | GPR119 (0.31) | — | |
| SCHEMBL23061257 | 0.72 | — | — | |
| SCHEMBL2347024 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL22859634 | 0.66 | RORC (0.30) | — | |
| SCHEMBL23061243 | 0.66 | — | — | |
| SCHEMBL6374100 | 0.65 | RBP4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1352901-B1 | Process for the preparation of cyclic diketones | SYNGENTA PARTICIPATIONS AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-7135574-B2 | Converting substituted mono or bicyclic lactones in presence of an amine base and a catalytic amount of a cyanide or alkali or alkaline metal alcoholate, to a salt, reacting the salt with carbonyl compound containing an organic substituent | SYNGENTA CROP PROTECTION, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050159314-A1 | Process for the preparation of cyclic diketones | SCHNEIDER HERMANN (CH) | 2005-07-21 | — | — | US | disclosed |
| US-6855831-B2 | Process for the preparation of cyclic diketones | SYNGENTA CROP PROTECTION, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030199708-A1 | Process for the preparation of cyclic diketones | SYNGENTA CROP PROTECTION, INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1352901-A2 | Process for the preparation of cyclic diketones | Syngenta Participations AG (CH) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199708-A1 | Process for the preparation of cyclic diketones | XDH, NDUFS6, SQOR | MRGPRX1 4237/4885 |
| US-20050159314-A1 | Process for the preparation of cyclic diketones | NDUFS6, NDUFS4, NDUFV1 | MRGPRX1 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.